Skip to main content
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. — Investor Relations & Filings

Ticker · KYTX ISIN · US5019761049 US Manufacturing
Open in API
Filings indexed 149 across all filing types
Latest filing 2026-06-02 Declaration of Voting R…
Country US United States of America
Listing US KYTX

About Kyverna Therapeutics, Inc.

https://kyvernatx.com/

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases. The company's approach involves engineering a patient's own T cells into Chimeric Antigen Receptor (CAR) T-cells to target and deplete B cells, which are central to the pathology of many autoimmune disorders. By adapting a technology proven in oncology, Kyverna aims to reset the immune system and achieve a durable, treatment-free remission from a single infusion. Its lead product candidate, KYV-101, is an autologous, fully human anti-CD19 CAR T-cell therapy being investigated in clinical trials for conditions including lupus nephritis and multiple sclerosis.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” under Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing the specific vote tallies for director elections and auditor ratification at the 2026 Annual Meeting. This constitutes an official declaration of voting results at a shareholders’ meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (Code DVA).
2026-06-02 English
8-K
Board/Management Information Classification · 99% confidence The document is a Current Report on Form 8-K filed with the SEC. Item 5.02 specifically concerns the departure and appointment of senior officers (appointment of a new CFO and the transition of the outgoing CFO). This falls squarely under announcements of changes in the company's board of directors or senior management. Therefore, the correct classification is Board/Management Information (MANG).
2026-05-18 English
10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Board/Management Information Classification · 88% confidence The document is a Form 8-K current report filed with the SEC, with Item 8.01 announcing the appointment of a new Chief Commercial Officer. This constitutes a senior management change announcement, fitting the Board/Management Information category (MANG).
2026-05-04 English
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 22, 2026. It announces the issuance of press releases about clinical trial results and the hosting of a conference call to discuss these results. It also includes a presentation slide deck as an exhibit (Exhibit 99.1) related to the conference call. The document explicitly states that the presentation is furnished in connection with the conference call. The content focuses on disclosure of new data and the announcement of a conference call with slides, which aligns with an Investor Presentation. The document is not a full financial report, audit, or earnings release, but rather a presentation of new data and company updates to investors. Therefore, the appropriate classification is Investor Presentation (IP). The document length is 4137 characters, which is consistent with a detailed announcement and presentation but not a full report. Confidence is high given the clear description and context.
2026-04-22 English
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 20, 2026. It announces a press release about positive follow-up data from a clinical trial and mentions a conference call to review results. The document includes a press release as an exhibit and states that the information is furnished and not filed for certain regulatory purposes. The content is primarily an announcement of recent events and a press release, not a full financial report or detailed earnings release. The document length is 3808 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-04-20 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.